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Abstract
Background: The World Health Organization predicts that by 2030 diabetes will be the seventh leading cause of
death in the world. Multiple studies have tried to determine if cinnamon is an effective treatment for diabetes.
Cinnamon extract is an insulin sensitizer, protects mesangial cells, decreases inflammatory markers, and lowers
glucose, lipids, and blood pressure in patients with type 2 diabetes, so we developed a protocol to study whether
ingestion of water-soluble cinnamon extract prevents progression from pre-diabetes to diabetes.
Methods/design: This is a randomized, double-blind, placebo-controlled trial comparing cinnamon extract versus
placebo in subjects with pre-diabetes who have committed to participate in a lifestyle change program. The trial
will be conducted at five sites and will include 428 subjects who take cinnamon extract or placebo for 1 year.
Follow-up for these subjects will be for a total of 2 years (nine study visits). The primary outcomes to be assessed
are 1) conversion of patients from pre-diabetes to diabetes and 2) impact of water-soluble cinnamon extract on
hepatic transaminases, renal function, and QT interval on electrocardiogram. Secondary outcomes include changes
in HbA1c, lipids, waist circumference, weight, blood pressure, and fasting plasma glucose. The trial protocol has
been approved by the Institutional Review Board of the US Air Force 59th Medical Wing, Wilford Hall Ambulatory
Surgical Center (Protocol FWH20110035H). Investigator-sponsored Investigational New Drug status (114078) was
granted by the US Food and Drug Administration.
Discussion: This study will provide high-quality evidence of the efficacy of water-soluble cinnamon extract in
conjunction with lifestyle intervention for preventing patients with pre-diabetes from converting to diabetes.
Additionally, it will provide important safety information about water-soluble cinnamon extract.
Trial registration: ClinicalTrials.gov Identifier: NCT01301521, 18 February 2011.
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Background
The worldwide incidence and prevalence of diabetes has
reached epidemic levels—the World Health Organization
predicts that by 2030 diabetes will be the seventh leading
cause of death in the world [1]. Along with new drugs that
target various methods for reducing blood sugar levels,
more natural substances are also being investigated. One
such therapy that has shown potential is cinnamon, which
is purported to be a natural insulin sensitizer and has been
studied and promoted worldwide.
Animal studies have suggested that cinnamon upregu-
lates mouse adipocyte insulin receptors and may inhibit
glycation end products. In previous studies, the use of cin-
namon extract (CE) has been demonstrated to ameliorate
intestinal insulin resistance and may be beneficial in the
control of lipid metabolism [2]. Rafehi and colleagues [3]
continue to study the changes in gene expression caused
by Cinnulin PF, while Luo and colleagues [4] isolated three
new phenolic glycosides, cinnacassosides A-C (1-3), to-
gether with 15 known compounds from the water-soluble
extract of Chinese cinnamon and tested these isolates in
mesangial cells to determine if cinnamon extract is useful
in preventing diabetic nephropathy. They found that five
unnamed compounds could inhibit over-secretion of IL-6,
collagen IV, and fibronectin against high-glucose-induced
mesangial cells. Additionally, in the presence of
water-soluble cinnamon extract [5], the expression of
genes coding glucose transporter (GLUT) increased
GLUT1. Furthermore, CE decreased the expression of
further genes encoding insulin-signaling pathway pro-
teins [6].
Multiple randomized controlled trials (RCTs) of various
size and quality studying cinnamon in humans with type 2
diabetes have been published with conflicting results
[7–12]. Two studies showed a possible effect of cin-
namon on fasting serum glucose, but hemoglobin A1c
(HbA1c) levels were not examined [6, 7]. One study
showed no effect on plasma glucose [9]. Two studies
involving both type 1 and type 2 diabetes showed no
effect of cinnamon on HbA1c [10, 11]. Cinnulin PF
supplementation reduced fasting blood glucose and
systolic blood pressure and increased lean body mass
in an RCT of men and women with metabolic syn-
drome [12]. A meta-analysis of these studies in diver-
gent populations showed no effect of cinnamon on
HbA1c, glucose, or lipids [13]. In contrast, an RCT of
109 patients compared add-on treatment with 1 gram
daily of cinnamon over a 3-month period to typically
accepted care in a population of poorly controlled
type 2 diabetics. Cinnamon lowered HbA1c an average of
0.83 %, which was similar to the effect of some prescrip-
tion drugs [14]. This led to a call for more comparative
research on the effectiveness of cinnamon versus prescrip-
tion medications [15]. A study from 2013 found little
effect of cinnamon on glucose levels in type 2 diabetes
[16], and a Cochrane review that included both type 1 and
type 2 diabetes found no effect of cinnamon on glucose
levels [17]. However, a rigorous meta-analysis limited to
evaluating the effect of cinnamon on type 2 diabetes only
(10 randomized, controlled trials, n = 543 patients) found
that “cinnamon doses of 120 mg/day to 6 g/day for 4 to
18 weeks reduced levels of fasting plasma glucose
(−24.59 mg/dL; 95 % CI, −40.52 to −8.67 mg/dL), total
cholesterol (−15.60 mg/dL; 95 % CI, −29.76 to −1.44 mg/
dL), LDL-C (−9.42 mg/dL; 95 % CI, −17.21 to −1.63 mg/
dL), and triglycerides (−29.59 mg/dL; 95 % CI, −48.27 to
−10.91 mg/dL). Cinnamon also increased levels of HDL-C
(1.66 mg/dL; 95 % CI, 1.09 to 2.24 mg/dL). No significant
effect on HbA1c levels (−0.16 %; 95 %, CI −0.39 % to
0.02 %) was seen” [18]. Further studies since the meta-
analysis found that the use of cinnamon significantly
decreased both systolic and diastolic blood pressure by
5.39 mm Hg (95 % CI, −6.89 to −3.89) and 2.6 mm Hg
(95 % CI, −4.53 to −0.66), respectively [19].
A survey of South Africans with both type 1 and type
2 diabetes found that more than 80 % of those surveyed
were aware of the postulated positive effect of cinnamon.
Thirty-six percent took cinnamon for prevention and
13 % for improved quality of life, but only 4 % took it to
treat diabetes. Up to 85 % reported some degree of will-
ingness to test the effect of cinnamon on blood glucose
[20]. Residents of Sydney, Australia were also likely to
try cinnamon [21]. These results support the chances
that a large trial will be able to recruit adequate subjects.
Current recommendations from the American Diabetes
Association regarding the treatment of pre-diabetes state
that individuals with pre-diabetes should receive either in-
tensive lifestyle intervention or metformin (Glucophage)
therapy to prevent progression to diabetes [22]. In light of
evidence that cinnamon extract (CE) is an insulin
sensitizer, protects mesangial cells, decreases inflam-
matory markers, and lowers glucose, lipids, and blood
pressure in patients with type 2 diabetes, we developed a
protocol to study whether ingestion of water-soluble CE
prevents progression from pre-diabetes to diabetes.
Methods/design
This is a randomized, double-blind, placebo-controlled
trial comparing CE versus placebo in subjects with pre-
diabetes who have committed to participate in a lifestyle
change program. The trial will be conducted at five sites
and will include 428 subjects who take CE or placebo
for 1 year. Follow-up for these subjects will be for a total
of 2 years (nine study visits) and measure progression to
diabetes and safety of CE. The trial protocol has been
approved by the Wilford Hall Ambulatory Surgical Center
Institutional Review Board (IRB) of the US Air Force 59th
Medical Wing (Protocol FWH20110035H). Investigator-
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sponsored Investigational New Drug status (114078) was
granted by the US Food and Drug Administration.
Informed consent is obtained from all subjects.
Outcomes
Primary outcomes
The primary outcomes to be assessed are 1) conversion
of patients from pre-diabetes to diabetes and 2) impact
of water-soluble CE on hepatic transaminases, renal
function, and QT interval on electrocardiogram.
Secondary outcomes
Other outcomes include changes in HbA1c, lipids, waist
circumference, weight, blood pressure, and fasting
plasma glucose.
Participating centers
The lead site is the 99th Medical Group at the Mike
O’Callaghan Federal Medical Center, Las Vegas, Nevada.
Other participating sites include the 59th Medical Wing
at the San Antonio Military Medical Center, San Antonio,
Texas; the 96th Medical Group at Eglin Regional Hospital,
Fort Walton Beach, Florida; the 60th Medical Group at
David Grant Medical Center, Vacaville, California; and the
55th Medical Group, Omaha, Nebraska.
Recruitment
Patients will be referred by their primary care team to
an approved lifestyle intervention for pre-diabetes. Inter-
ventions include Group Lifestyle Balance (GLB) instruction
(a comprehensive, evidence-based, lifestyle behavior change
program adapted directly from the National Institutes of
Health funded Diabetes Prevention Program), nutrition
classes, Better Body/Better Life, or other sessions that an in-
vestigator has certified as standard practice at that hospital.
Patients attending these lifestyle interventions will be of-
fered the opportunity to participate in this trial. Potential
subjects are a combination of active duty military members
and their families and retired military members and their
families. Each of these Air Force medical treatment facilities
treats the full range of ages and medical conditions.
The initial screening visit will include signing informed
consent and HIPAA Authorization forms and initiating a
record including standard demographic and contact
information, name of lifestyle intervention for pre-
diabetes, height, weight, waist circumference, and blood
pressure. In addition, any use of statins, fibrates, niacin,
or bile acid binding agents will be documented, and
women of childbearing potential will have a serum preg-
nancy test. Subjects will be told to fast for at least
10 hours prior to their first visit.
Inclusion criteria
Subjects included will be men and women aged 18–65
years; military beneficiaries receiving medical care at one
of the participating sites; meeting diagnostic criteria for
pre-diabetes [defined as fasting plasma glucose (FPG) of
100–125 mg/dl, a HbA1c of 5.7–6.4 %, or a 2-hour oral
glucose tolerance test (OGTT) of 140–199 mg/dl].
Exclusion criteria
Potential participants will be excluded from the study if
they meet the following criteria: existing diagnosis of
diabetes mellitus (defined as FPG ≥126 mg/dl, HbA1C
≥6.5 %, or a 2-hour OGTT ≥200 mg/dl); stage 3 or greater
kidney disease [renal insufficiency defined as a glomerular
filtration rate (GFR) of less than 60 ml]; celiac disease;
insulinoma; Cushing’s disease; hyperthyroidism; acromeg-
aly; pheochromocytoma; Addison’s disease; galactosemia;
glycogen storage disease; hereditary fructose intolerance.
Subjects already taking 1) cinnamon as a dietary supple-
ment, 2) daily oral steroids, 3) warfarin, 4) antidiabetic
medication, 5) weight loss medication, or 6) medications
with narrow therapeutic indices (to include digoxin,
lithium, phenytoin, and theophylline) will be excluded.
Patients who are pregnant or breast feeding, known
to be allergic to cinnamon or wheat (used in the placebo),
and special populations will be excluded from this study.
Randomization and blinding
Randomization was performed using a computer-
generated randomization code in block sizes of 10 to
ensure roughly equal sample sizes between study arms
in case the trial was to be terminated early. This also
allowed for an equal number of subjects to be enrolled
in each arm at the individual sites. After consent, sub-
jects will be randomized by an independent investigator
not involved with subject interactions. The investiga-
tional product (IP) and placebo were manufactured in
identical-looking gelatin capsules that each contain
500 mg of water-soluble cinnamon extract (Cinnulin PF)
or wheat bran, respectively. Prior to the study start, IP
and placebo were packaged in identical-looking opaque
bottles and labeled by a team of pharmacists at the 60th
Medical Group who would not dispense medication to
any subject. The blinded and randomized product was
shipped to each participating site for sequential enroll-
ment of study subjects. This team then sent the blind-
labeled IP and placebo to participating sites along with
predesignated, randomized slips designating which bottle,
A or B, a subject received. A random number generator
and blocking in groups of 4 were used to ensure roughly
equal sample sizes at each site. Subjects, dispensing phar-
macists, research personnel, laboratory technicians, and
investigators are all blinded to the study group assign-
ments. In case of an emergency, the enrollment site’s
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pharmacy is to be called, and only the individual subject
would be unblinded. Both IP and placebo are in identical
capsules with no particular aftertaste or odor.
After enrollment, subjects randomized to consume
Group A will be prescribed 2 gelatin capsules that each
contain 500 mg of water-soluble cinnamon extract
(Cinnulin PF) and will be instructed to take 2 capsules
once a day by mouth. Subjects are to be dispensed a 3-
month supply of blinded product at each site visit for a
total study duration of 1 year in addition to standard of
care aggressive lifestyle therapy. Group B will be pre-
scribed 2 placebo capsules (gelatin capsule filled with
wheat bran) once a day by mouth for 1 year in addition to
standard of care aggressive lifestyle therapy. Each group
will have the identical number of follow-up visits over
1 year with additional follow-up for 1 year after complet-
ing the study medication. Compliance with medications is
to be determined with every visit using a medication
adherence diary completed daily and reviewed by the
study coordinators at each visit by each subject.
Intervention
Cinnulin PF is manufactured by Integrity Nutraceuticals
under Good Manufacturing Practices (GMP) and is
certified by the National Sanitation Foundation (NSF).
Cinnulin PF is an extract of Cinnamomum burmannii. A
purported benefit of Cinnulin PF is that through process-
ing almost all toxic coumarins are removed. The investiga-
tive team sent a sample of both the Cinnulin PF and
placebo for toxicology analysis to Expertox Laboratory
(Deer Spring, TX), and no toxin or adulterant was found
in either item.
Procedure and strategies for retention
After screening, visit 1 is to be completed within one
week of the screening visit. A baseline medication list
will be obtained, and a RAND 36 survey will be com-
pleted to measure quality of life. A non-investigator in
the pharmacy will randomize subjects after visit 1. Sub-
jects will be provided a pill container to assist with re-
membering to take their IP and a bathroom scale for
weight measurement along with a “Blood Test Reminder
Card,” which they will be instructed to show to their pri-
mary care team when laboratory tests are to be ordered
to avoid duplication of tests. During visits 2 through 9,
measurements to include weight, waist circumference,
and blood pressure will be obtained; medication updates
will also be obtained. At visits 5 and 9, the RAND 36
questionnaire will be repeated. Follow-up visits 2
through 9 occur 90 days after previous visit plus or
minus a 10-day visit window. Subjects are given their
90-day supply of IP and encouraged to meet the 90-day
mark as closely as possible. By visit 5, subjects should
have completed taking all of their study medication.
Safety assessments
All women will receive a pregnancy test at visit 1 and be
instructed to use two forms of birth control while taking
IP. All subjects will be questioned about adverse events
(defined as any new symptom) at each visit, and all ad-
verse events reported will be analyzed, regardless of the
investigators’ assessment of causality. Research Monitors
have been appointed by the IRB, and the IRB reviews ad-
verse events annually. As part of the Investigational New
Drug approval, the FDA requires safety to be assessed by
complete blood cell count, liver transaminases, blood
chemistry, and urinalysis. Cardiovascular events and
other cardiovascular morbidity data will also be assessed
by post hoc analysis. Electrocardiograms will be per-
formed only at visits 1 and 2 to document QT intervals
as part of the safety monitoring plan. Ad hoc analysis of
these electrocardiograms is expected to take place after
100 subjects complete study visit 2.
Subjects are to be given a Study Medication Diary and
will be instructed to bring it with them to each study
visit. Subjects will be instructed to fast for at least
10 hours prior to each visit. HbA1c and a serum lipid
panel (cholesterol, triglycerides, HDL, LDL) will be per-
formed at each visit. Fasting comprehensive metabolic
panel (liver function, renal function, plasma glucose
tests) will be performed at visits 1 through 6 only, and a
fasting plasma glucose and HbA1c will accomplished at
visits 7 through 9 only. Subjects who have any of these
laboratory tests done two weeks prior to a visit will not
need to have these tests repeated since variability of
these tests is minimal.
Strategies for retention
Post visit 2, subjects will be seen every 90 days with a
window of plus or minus 10 days. Postponement of any
6-month periodic visit is authorized for up to 6 weeks in
case of a temporary condition that would affect glucose
tolerance (that is, moderate to severe illness to be deter-
mined by study PI or site AI). Adherence to study medica-
tion will be assessed via review of the Study Medication
Diary and recorded compliance. If a subject misplaces
their Study Medication Diary, they will be asked to repro-
duce it from memory to the best of their ability. Subjects
will be instructed to bring back all of the medication bot-
tles, and remaining pills, if any, are to be discarded.
If at any time a subject stops taking his/her Cinnulin
PF or placebo, he/she will remain in the study but is to
be instructed to return any pills for documentation. Dur-
ing each of their follow-up contacts, research staff will
offer them the opportunity to re-start their Cinnulin PF or
placebo. Regardless of the amount of missed doses, all
subjects are to remain in the study so that intent-to-treat
analysis can be carried out and to continue with all of the
study-related visits. If the subject decides to re-start their
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Cinnulin PF or placebo, they will resume the study at their
last documented visit.
If subjects misplace or lose their study medication,
they will be instructed to return to the pharmacy and
will be given a new bottle from the same group of their
assigned study medication. If a subject forgets to bring
their study medication to a scheduled visit, they will be
instructed to return it at their earliest convenience.
Biostatistical considerations
Two null hypotheses will be tested: 1) H01 - There is no
difference in means of continuous dependent variables
between and among treatment groups. 2) H02 - Both the
Cinnulin PF + Lifestyle and Placebo + Lifestyle groups
have identical survival functions for the time to reach
the type 2 diabetes conversion event.
Sample size estimation and power analysis
A priori power for H01 was assessed using G*Power Ver-
sion 3.0.10 [23]. 214 subjects per group with 8 repeated
measures (for a total sample size of 428 × 8 = 3424) will
achieve a power of approximately 0.99 to detect a small
effect size of 0.10 at α = 0.0004.
Post hoc analyses to evaluate differences within clinically
significant time intervals will be tested with one-tailed t-
tests for independent samples. The power analysis, using
G*Power Version 3.0.10, shows that 214 subjects per
group will achieve a power of approximately 0.85 to detect
a small effect size of 0.20. To lessen the probability of a
false negative, a β/α ratio of 1 was employed.
A priori power for H02 was assessed using the method
described by Glantz [24] to calculate sample size for a
two-sample log-rank test to detect differences in the
time to event. Based on this design, it will require a mini-
mum of 214 subjects per group to detect a difference be-
tween a 17.5 % conversion in the Placebo + Lifestyle and
an 11.5 % conversion in the Cinnulin PF + Lifestyle group
at α = 0.05 (one-sided) and power of 0.80.
Steps of analysis
The experimental design of this study is a mixed effects,
randomized complete block design with repeated mea-
sures. “Subject” is a random effect, as the subjects are a
sample randomly selected and randomly assigned to a
treatment group. Fixed effects are treatment group and
time of repeated measure, as these effects cannot be
generalized to other treatments and times. Subjects will
be randomly assigned to each group.
Factors to be included in the analysis are 1) Subject, 2)
Treatment (Cinnulin PF + Lifestyle Management versus
Placebo + Lifestyle Management), and 3) Repeated Mea-
surements (laboratory and physical measurements obtained
from each subject at fixed intervals for the duration of the
study (N = 8)).
Outcome variables include plasma glucose, HbA1c,
lipid panel (cholesterol, triglycerides, HDL, LDL), waist
circumference, and conversion to type 2 diabetes (Yes/No).
Subject demographics to be collected include age, gen-
der, and race/ethnicity (African American, European
American, or Hispanic, Other).
Descriptive statistics
Sample means and standard errors of measurement of
interval variables will be calculated, and frequency distri-
butions of nominal variables will be calculated and
graphed for the total sample and for the Cinnulin PF/
Lifestyle Management groups. Homogeneity of the
groups will be tested with a two-tailed t-test and a chi-
square or Fisher’s exact test for interval and nominal
variables, respectively.
Hypothesis testing
H01 – This hypothesis will be tested by a mixed effects
repeated measures analysis of variance (rANOVA).
H02 – This hypothesis will be tested by developing
Kaplan-Meier survival curves and survival functions
compared with a log-rank test.
Post hoc tests
In the event H01 is rejected, contrasts will be used to
investigate effects and differences within clinically sig-
nificant time intervals. In the event multiple univariate
tests are used to investigate effects, the Bonferroni [25]
or Holm [26] method will be used to correct the level of
significance for multiple comparisons.
Discussion
This study will provide high-quality evidence of the effi-
cacy of water-soluble CE in conjunction with lifestyle
intervention for preventing patients with pre-diabetes
from converting to diabetes. Additionally, it will provide
important safety information about water-soluble CE.
Non-communicable diseases (NCDs) such as diabetes
cause 63 % of all deaths worldwide, so strategies to miti-
gate and reduce the health burden of NDCs are important
to improve health around the world [27]. Searching out
natural compounds to prevent diabetes, verifying efficacy,
and proving safety should be a priority [28].
Trial status
Recruitment commenced on 11 June 2013, and the trial
is scheduled to end in September 2016.
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